Drug intelligence / Profile preview

long-acting PTH

Development stage: Preclinical
Lead developer: OPKO Biologics
Modality: Peptides, Recombinant Proteins and Enzymes
Administration: Oral, Subcutaneous

Overview

Long-acting PTH (LA-PTH) is a proprietary parathyroid hormone variant being developed by OPKO Biologics for the treatment of hypoparathyroidism. It is a stabilizer-based long-acting protein/peptide analog designed to provide sustained activation of the parathyroid hormone receptor, aiming to maintain stable calcium and phosphorus levels in patients with chronic PTH deficiency. OPKO is collaborating with Entera Bio to develop an oral, once-daily tablet formulation of this variant using Entera's N-Tab technology, which could potentially eliminate the need for daily injections. The program is currently in preclinical development, with an Investigational New Drug (IND) application targeted for late 2026.

Other names: LA-PTHlong-acting parathyroid hormone

Targets

PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)PTH2R (Parathyroid hormone 2 receptor)

Beyond the preview

Go deeper on long-acting PTH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on long-acting PTH.

Explore the full profile